/C O R R E C T I O N — RyboDyn/

/C O R R E C T I O N -- RyboDyn/

giovedì 9 luglio 2026 New tab

1,121 words~5 min read

/C O R R E C T I O N -- RyboDyn/

PR Newswire

SAN DIEGO, July 9, 2026

In the news release, RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG CANCER, issued 09-Jul-2026 by RyboDyn over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG CANCER

/C O R R E C T I O N — RyboDyn/

/C O R R E C T I O N — RyboDyn/

Related reading

RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG…

/C O R R E C T I O N — Ranok Therapeutics/

/C O R R E C T I O N — Radial Health, Inc./

/C O R R E C T I O N — Acurion/

/C O R R E C T I O N — Dispensary of Hope/

/C O R R E C T I O N — Kedrion Biopharma/

Related reading

RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG…

/C O R R E C T I O N — Ranok Therapeutics/

/C O R R E C T I O N — Radial Health, Inc./

/C O R R E C T I O N — Acurion/

/C O R R E C T I O N — Dispensary of Hope/

/C O R R E C T I O N — Kedrion Biopharma/